Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lentivirus-like particles without reverse transcriptase elicit efficient immune responses.

Sean P McBurney1, Kelly R Young, Casmiar I Nwaigwe

  • 1Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA.

Current HIV Research
|November 1, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of Igκ and Igλ binding toward influenza virus hemagglutinin and SARS-CoV-2 Spike protein during primary viral infections in humans, mice, and pigs.

Comparative immunology, microbiology and infectious diseases·2026
Same author

Antigenic mapping of H2 influenza viruses recognized by ferret and human sera and predicting antigenically significant sites.

mSphere·2026
Same author

Microplastics inhibit macrophage bioenergetics impairing homeostatic function and immune responsiveness.

bioRxiv : the preprint server for biology·2026
Same author

Intramuscular administration of influenza hemagglutinin in one hind leg elicits similar protective immune responses as administration in two hind legs.

Virology·2026
Same author

Chronic exposure to aerosolized Arizona test dust reduces visual acuity in mice.

Toxicology reports·2026
Same author

Retooling a novel influenza B hemagglutinin to redirect neutralizing antibodies against B/Victoria strains.

Vaccine·2026
Same journal

Human Papillomavirus (HPV)-The Interplay between Vaginal Microbiota and HPV, along with its Prevention.

Current HIV research·2026
Same journal

Metabolic Syndrome Prevalence Among People Living With HIV: A Single-Center Study From Türkiye.

Current HIV research·2026
Same journal

Weight Change with Long-Acting Cabotegravir Plus Rilpivirine in People with HIV: Targeted Review and Meta-Analysis.

Current HIV research·2026
Same journal

Corrigendum to: Impact of HIV-1 Tat on FDFT1 Suppression, Changes in Cholesterol Level, and KSHV Replication in BCBL1 Cells.

Current HIV research·2026
Same journal

Study of Class I HDAC-1, -2, and -3 Inhibitors Designed by Bioisosteric Replacement of Zinc Binding Groups and Caps of Traditional Pan Inhibitors: An <i>In Silico</i> Approach.

Current HIV research·2026
Same journal

Sociodemographic and Clinical Characteristics of Individuals Receiving Post-Exposure Prophylaxis (PEP) for HIV in the Republic of Cyprus: A Cross-sectional Study.

Current HIV research·2026
See all related articles

Developing novel virus-like particles (VLPs) for an AIDS vaccine, researchers created versions with and without enzymatically active reverse transcriptase (RT). Both VLP types demonstrated strong immune responses in mice, suggesting RT-deleted VLPs offer enhanced safety for clinical trials.

Area of Science:

  • Virology
  • Immunology
  • Vaccine Development

Background:

  • Reverse transcriptase (RT) is crucial for HIV/SIV replication but poses safety concerns for vaccine development due to its enzymatic activity.
  • Incorporating immunogenic epitopes from RT into an AIDS vaccine is desirable, but safety issues have limited enthusiasm.
  • Virus-like particles (VLPs) offer a potential platform for vaccine candidates, but their immunogenicity and safety profiles require careful optimization.

Purpose of the Study:

  • To evaluate the immunogenicity and safety of lentiviral virus-like particles (VLPs) with and without enzymatically active reverse transcriptase (RT) for potential use in HIV/AIDS vaccine development.
  • To determine if removing or inactivating RT from VLPs impacts the overall immune response against key viral antigens.
  • To assess the suitability of RT-deleted VLPs for future human clinical trials by examining their safety and efficacy in eliciting immune responses.

Related Experiment Videos

Main Methods:

  • Replication-incompetent lentiviral particles (VLPs) were engineered by deleting essential genes (integrase, Vpr, Vif, Nef, LTRs) and modifying capsid to reduce RNA packaging.
  • Two types of VLPs were produced: those lacking RT entirely (HIV-VLP DeltaRT) and those containing an enzymatically inactivated RT molecule (HIV-VLP).
  • BALB/c mice were immunized intranasally with purified VLPs in the presence of CpG oligodeoxynucleotides (CpG ODNs) at weeks 0, 3, and 6, followed by assessment of humoral and cellular immune responses.

Main Results:

  • All generated VLPs, irrespective of the presence or enzymatic activity of RT, successfully elicited robust humoral and cellular immune responses.
  • Immune responses were directed against key viral antigens including Gag, Pol, and Env, indicating broad immunogenicity.
  • No significant reduction in overall immunogenicity was observed in VLPs lacking enzymatically active RT compared to those containing it.

Conclusions:

  • Virus-like particles (VLPs) lacking enzymatically active reverse transcriptase (RT) are safe and immunogenic, presenting a promising avenue for HIV/AIDS vaccine development.
  • The absence of active RT in VLPs enhances their safety profile for potential human clinical trials without compromising the induction of crucial immune responses.
  • These findings support the further investigation of RT-deleted VLPs as a viable and safer alternative for future AIDS vaccine candidates.